Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Natalia Skobeleva"'
Autor:
Erica A. Golemis, Yanis Boumber, David A. Proia, Brian L. Egleston, James S. Duncan, Kelly E. Duncan, Kathy Q. Cai, Luisa S. Ogawa, Vladimir Khazak, Natalia Skobeleva, Alexander E. Kudinov, Meghan C. Kopp, Alexander Y. Deneka, Anna S. Nikonova, Anna V. Gaponova
Supplemental Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a68d063d839114f344a6d0c801dfd9
https://doi.org/10.1158/1078-0432.22465676
https://doi.org/10.1158/1078-0432.22465676
Autor:
Erica A. Golemis, Yanis Boumber, David A. Proia, Brian L. Egleston, James S. Duncan, Kelly E. Duncan, Kathy Q. Cai, Luisa S. Ogawa, Vladimir Khazak, Natalia Skobeleva, Alexander E. Kudinov, Meghan C. Kopp, Alexander Y. Deneka, Anna S. Nikonova, Anna V. Gaponova
Supplemental Materials and Methods and supplemental figure legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e9479d8cd89b1f7616febae6150cb09
https://doi.org/10.1158/1078-0432.22465682.v1
https://doi.org/10.1158/1078-0432.22465682.v1
Autor:
Erica A. Golemis, Yanis Boumber, David A. Proia, Brian L. Egleston, James S. Duncan, Kelly E. Duncan, Kathy Q. Cai, Luisa S. Ogawa, Vladimir Khazak, Natalia Skobeleva, Alexander E. Kudinov, Meghan C. Kopp, Alexander Y. Deneka, Anna S. Nikonova, Anna V. Gaponova
Purpose: Small cell lung cancer (SCLC) is a highly aggressive disease representing 12% to 13% of total lung cancers, with median survival of Experimental Design: To avoid DLT for useful cytotoxic agents, the recently developed drug STA-8666 combines
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::266ec2e3cf6921d5fb1589a082eccc18
https://doi.org/10.1158/1078-0432.c.6526112
https://doi.org/10.1158/1078-0432.c.6526112
Publikováno v:
Medical news of the North Caucasus. 18
Autor:
Vladimir Khazak, Mark Andrake, Brian L. Egleston, Neil Beeharry, Natalia Skobeleva, James C. Hittle, Jeffrey R. Peterson, Sean Deacon, Timothy J. Yen, Igor Astsaturov, Eugenia Banina
Publikováno v:
Cell Cycle. 13:2172-2191
Inhibitors of the DNA damage checkpoint kinase, Chk1, are highly effective as chemo- and radio-sensitizers in preclinical studies but are not well-tolerated by patients. We exploited the promiscuous nature of kinase inhibitors to screen 9 clinically
Autor:
David A. Proia, Natalia Skobeleva, Vladimir Khazak, Igor Astsaturov, Natalya Beglyarova, Egor Bobrov, Kathy Q. Cai, Diana Restifo, Elizabeth Handorf, Erica A. Golemis, Kerry S. Campbell
Publikováno v:
Oncotarget
The lack of effective treatment modalities is a major problem in pancreatic cancer (PCa), a devastating malignancy that is nearly universally driven by the “undruggable” KRAS and TP53 cancer genes. Poor tumor tissue penetration is the major sourc
Autor:
Anna Czarna, Günther Ross, Lutz Weber, Natalia Skobeleva, Cedric Kalinski, Tad A. Holak, Marcin Krajewski, Jolanta Ciombor, Vladimir Khazak, Ulli Rothweiler
Publikováno v:
ChemMedChem. 3:1118-1128
p53 has been at the centre of attention for drug design since the discovery of its growth-suppressive and pro-apoptotic activity. Herein we report the design and characterisation of a new class of isoquinolinone inhibitors of the MDM2-p53 interaction
Publikováno v:
Molecular Cancer Therapeutics. 6:898-906
An important clinical task is to coherently integrate the use of protein-targeted drugs into preexisting therapeutic regimens, with the goal of improving treatment efficacy. Constitutive activation of Ras-dependent signaling is important in many tumo
Autor:
Natalia Skobeleva, Anastasiia Vetkina, Vladimir Khazak, Ilya G. Serebriiskii, Angela M. Davies, Igor Astsaturov, Kirsten Timms
Publikováno v:
Cancer Research. 77:1124-1124
Pancreatic ductal adenocarcinoma (PDAC) is a devastating malignancy that affects 44,000 individuals annually in the US, with almost 90% lethality even when diagnosed prior to metastasis. There is an urgent unmet medical need both for new therapies as
Autor:
Lev Petrenko, Gösta Winberg, R. Z. Gizatullin, Vladimir I. Kashuba, Raf M. Podowski, Veronika V. Zabarovska, Eugene R. Zabarovsky, Li Xie, Ingemar Ernberg, Natalia Skobeleva, Alexei Protopopov, Claes Wahlestedt, Olga V. Muravenko, Jingfeng Li, Sergei Kozyrev
Publikováno v:
Nucleic Acids Research. 28:1635-1639
Not I linking clones contain sequences flanking Not I recognition sites and were previously shown to be tightly associated with CpG islands and genes. To directly assess the value of Not I clones in genome research, high density grids with 50 000 Not